tbuckley/cabot-search huggingface dataset:
A multivariate analysis of a series of 382 primary retroperitoneal sarcomas (RPS)
Authors: M. Rivoire, S. Bonvalot, M. Castaing, E. Stoeckle, A. Laplanche, A. Le Cesne
Journal: Journal of Clinical Oncology (2007)

10065 Background: A national retrospective study was conducted by the French Association of Surgery on primary RPS in order to define the best type of surgery and determine prognostic factors for abdominal recurrence and patient survival. There is still no consensus concerning the precise value of the extent of surgery and additional treatment modalities. Methods: Types of surgery were classified as: “systematic complete resection”, which is a systematic or partial resection of non-involved contiguous organs to achieve wide margins, “contiguously involved organ resection” and “simple complete resection”, a resection of the tumor with grossly negative margins. Survival was determined with the Kaplan-Meier method. Univariate and multivariate prognostic analyses were performed using logrank test and Cox model. Results: Data of 382 pts operated between 1985 and 2005 were retrospectively reviewed. Median age was 57 years (range 14–87). Median tumor size was 18 cm. Systematic complete resection, contiguously involved organ resection and simple complete resection were performed for 134 (35%), 153 (40%) and 87 (23%) pts, respectively. Eight pts (2%) had a biopsy without resection and 45 pts (12%) had macroscopic residual disease. Tumor was spilled during surgery for 76 pts (20%). Systematic complete resection and no spilling of the tumor were highly correlated with the number of pts operated by center (p-values &lt;10 -4 ). Histologic negative margins (136 pts, 36%) were highly correlated with systematic complete resection (p-value &lt;10 -4 ). Chemotherapy and radiotherapy were given to 135 (35%) and 122 pts (32%). Median survival was 6 years whereas median time to abdominal recurrence and metastasis were 4 and 15 years, respectively. On multivariate analysis, pre op biopsy, low grade, no spilling of the tumor, negative margins and number of pts operated by center were the significant factors predicting abdominal recurrence control whereas low grade, no spilling of the tumor and no macroscopic residual disease significantly predicted better overall survival. Conclusions: Tumor grade and quality of surgery were the two main prognostic factors for abdominal recurrence and overall survival. Surgical experience of these rare tumors and systematic complete resection decreased abdominal recurrence rate. No significant financial relationships to disclose.
Bioinformatic approaches elucidate a high likelyhood of interaction between miR-182 and the pro-apoptotic gene MTCH2 in breast cancers.
Authors: Benjamin Howell Lole Harris, Simon Wigfield, Adrian L. Harris, Francesca Meteora Buffa
Journal: Journal of Clinical Oncology (2015)

e12551 Background: Hypoxia is a feature of solid tumours and is associated with malignant progression. Changes in gene-expression have been demonstrated in hypoxic tumours and in vitro systems. Previously, tumour expression patterns were empirically correlated with prognosis but prognostic signatures were derived without reference to the functional roles of their components. This laboratory has developed a seed-clustering approach based on knowledge of hypoxia biology to simplify these signatures. The current work uses this approach to identify new genes regulated by hypoxia and predict prognosis in hypoxic tumours. Methods: Differential gene expression associated with the presence of LDH-A and LDH-B was investigated using bioinformatic approaches to identify metabolic pathways associated with expression of individual isoforms. One promising gene was MTCH2, whose expression followed that of LDH-A. The bioinformatic work was supplemented by immunochemical and RNA studies on tumour cells. Results: Bioinformatics shows an inverse correlation between miR-182 expression and expression of MTCH2 in tumours (152 patients), suggesting possible control of expression by this miRNA. miRNA target prediction tools show a strong probability of interaction. Using cultured human breast cancer cells (ER positive & ER negative) directly, a HIF-1α modulated protein was observed to increase in hypoxia which reacted with anti-MTCH2 antibody. However, knockout studies indicated that the protein varying in these lines was not conventional MTCH2, which decreased under hypoxia. Attempts to identify the immunoreactive protein proved inconclusive. Measurement of miR-182 indicated that its level rose under hypoxia in the two cell lines studied. Conclusions: Bioinformatic analysis, using RNA extracted from primary tumours, identified MTCH2 as a hypoxia-induced protein. This observation could not be directly transferred to in vitro cell lines although an MTCH2-like protein is induced by hypoxia in these lines. In both primary tumours and cell lines, there was an inverse relation between conventional MTCH2 and miR-182 levels. This may have implications for therapeutic use of miRNA.
Prognostic Impact of a Novel Biomarker, Serum Soluble LR11 on Acute Leukemia
Authors: Chikako Ohwada, Masahiro Takeuchi, Shio Sakai, Daijiro Abe, Yusuke Takeda, Naomi Shimizu, Emiko Sakaida, Takeharu Kawaguchi, Kohei Takubo, Hiroyuki Ebinuma, Isamu Fukamachi, Koutaro Yokote, Atsushi Iwama, Wolfgang J Schneider, Hideaki Bujo, Chiaki Nakaseko
Journal: Blood (2010)
Assessment of Minimal Residual Disease (MRD) by Qualitative RT-PCR (Q-PCR) vs Real-Time Quantitative RT-PCR (RQ-PCR) in a Phase II Study of Acute Promyelocytic Leukemia (APL).
Authors: Robert E. Gallagher, Esther L. Schachter-Tokarz, Dan A. Jones, Elihu H. Estey
Journal: Blood (2005)
Efficacy of siltuximab in patients with previously treated multicentric Castleman’s disease (MCD).
Authors: Frits Van Rhee, Nikhil C. Munshi, Raymond Wong, Xiaoyan Ke, Alexander Fossa, David Simpson, Angela Dispenzieri, Mary Jo Lechowicz, John Kuruvilla, Rajesh Bandekar, Xiang Qin, Ming Qi, Jessica Vermeulen, Corey Casper
Journal: Journal of Clinical Oncology (2014)

8514 Background: Siltuximab is a chimeric anti−IL-6 monoclonal antibody under investigation for treatment of MCD.A randomized, double-blind, placebo-controlled study in MCD showed significant improvement in durable tumor and symptomatic response (34.0% vs 0.0% with placebo; P = 0.001), superior response in the secondary endpoints of tumor response rate, time to treatment failure, MCD symptom improvement, and no increased frequency of adverse events compared with placebo. A prespecified subanalysis evaluated the efficacy of siltuximab among patients who had received prior systemic therapy. Methods: Adults with confirmed symptomatic MCD were randomized 2:1 to siltuximab 11 mg/kg (n = 53) or placebo (n = 26) IV every 3 weeks and were stratified by corticosteroid use at randomization. All patients received best supportive care, and treatment was continued until treatment failure. Results: The majority (siltuximab, n = 29 [54.7%]; placebo, n = 17 [65.4%]) of patients had received prior systemic treatment for MCD. The most frequently used agents included corticosteroids 93.5%, cyclophosphamide 50%, vincristine 26.1% and rituximab 17.4%. Durable tumor and symptomatic responses were similar for pretreated and treatment naïve subgroups (34.5 % vs 0% and 33.3 % vs 0% respectively). Secondary endpoints consistently favored siltuximab in both subgroups as presented in the Table. Frequencies of adverse events (AE) and serious (S) AEs were similar across pretreated and treatment naive subjects. Conclusions: Siltuximab is an active agent in both newly diagnosed MCD and patients who have insufficient response to or failed other therapies. Clinical trial information: NCT01024036. Pretreated MCD patients Treatment naïve MCD patients Siltuximab Placebo Siltuximab Placebo n 29 17 24 9 Durable tumor and symptom response by investigator 48% 0% 42% 0% Median time to treatment failure Not reached 184 days Not reached 177 days Hemoglobin increase > 1.5 g/dL in anemic subjects 59% (n = 17) 0% (n = 7) 64% (n = 14) 0% (n = 4) Durable complete symptomatic response 17% 0% 33% 0% Patients with AEs 100% 100% 100% 89% Patients with SAEs 24% 12% 21% 33%
THE INCIDENCE OF PERMANENT PACEMAKER IMPLANTATION WITH SAPIEN 3 HEART VALVE – IMPLANTATION DEPTH: THE HIGHER THE BETTER?
Authors: Fernando Ramirez Del Val, Edward Carreras, Ahmed Kolkailah, Ritam Chowdhury, Siobhan McGurk, Jiyae Lee, Prem Shekar, Charles Nyman, Piotr Sobieszczyk, Marc Pelletier, Tsuyoshi Kaneko, Douglas Shook
Journal: Journal of the American College of Cardiology (2017)
IPSILATERAL RESTING VENOUS LACTATE LEVELS DECREASED AFTER SUCCESSFUL PERCUTANEOUS REVASCULARIZATION OF THE LIMB IN PATIENTS SUFFERING INTERMITTENT CLAUDICATION
Authors: Harun Kilic, Yusuf Can, Murat Aksoy, Ersan Tatli, Tarik Agac, Mehmet Akif Cakar, Mustafa Gökhan Vural, Ramazan Akdemir, Gunduz Huseyin
Journal: Journal of the American College of Cardiology (2017)
Topotecan consolidation after etoposide platinum for limited stage small cell lung cancer patients who do not receive prophylactic cranial irradiation
Authors: H. J. Ross
Journal: Journal of Clinical Oncology (2009)

7553 Background: Small cell lung cancer (SCLC) accounts for approximately 15% of new lung cancer diagnoses in the US and about one third of patients present with limited stage (LD-SCLC). Concurrent chemoradiotherapy followed by prophylactic cranial irradiation (PCI) is standard and produces long-term survival in up to 25% of good performance status (PS) patients. Some patients refuse or are ineligible for PCI resulting in poorer outcome. Topotecan is active against SCLC and crosses the blood brain barrier suggesting that it might reduce brain metastases in this group. This phase II trial was designed to explore that possibility. Methods: Eligible patients had declined or were ineligible for PCI after completing standard platinum etoposide chemotherapy with concurrent radiotherapy for LD-SCLC with at least a partial response (PR), had recovered from toxicity with PS 0–1, and had no evidence of brain metastases. Patients received 1.5 mg/m2/day topotecan IV for 5 consecutive days every 21 days for four cycles. Primary endpoint was incidence of brain metastases with secondary endpoints overall and progression-free survival and toxicity. Results: Twenty patients enrolled between November 1999 and May 2006. 17 patients (85%) completed 4 cycles of topotecan. Brain metastases developed in 6 patients (30%) at a mean of 5.3 months (range 84–324 days). Median survival was 25.9 months with median PFS 462 days. At final data analysis, eight patients (40%) were alive without evidence of disease at 19 to 92.6 months. Topotecan was well tolerated with grade 3/4 hematologic toxicity in 13 patients (65%) and neutropenic fever in 2 patients. One patient had radiation pneumonitis. One patient died with progressive disease and pneumonia after two cycles of topotecan. Conclusions: Adjuvant topotecan was well tolerated. The 30% rate of brain metastases suggests the possibility that topotecan was active in the brain. Overall and progression-free survivals are promising. Additional study of adjuvant topotecan in LD-SCLC patients who do not receive PCI may be warranted. No significant financial relationships to disclose.
LATE INTERVENTION AFTER ENDOVASCULAR ANEURYSM REPAIR FOR ABDOMINAL AORTIC ANEURYSM: NATIONAL HOSPITAL ORGANIZATION NETWORK STUDY IN JAPAN
Authors: Masayuki Sakaki, Nobuhiro Handa, Toshihiro Onohara, Masakazu Kawasaki, Fuminori Kasashima, Masahiro Okada, Tsuyoshi Yamamoto, Minoru Okamoto, Masafumi Yamashita, Katsutoshi Sato, Shingo Ishiguro, Yasushi Shimoe, Jyunji Kishimoto
Journal: Journal of the American College of Cardiology (2017)
UNLOCKING THE POWER OF DATA: INFORMATION TECHNOLOGY IMPLEMENTATION FOR SMARTER MANAGEMENT AND RESOURCE USE FOR TODAY'S COMPLEX CARE DELIVERY
Authors: Thomas J. Lewandowski, Joe Allen, Anthony DeFranco, Allen Seals, Hector Fontanet, Nicole Lohr, Joshua Liberman, Ralph Brindis, Joshua Purow, Alvaro Gomez, Kenneth Phillips, Robert Wilson, Mustafa Ahmed, Nandkishore Ranadive, Sandra Groenewold, Juan Aranda
Journal: Journal of the American College of Cardiology (2017)
The Combination of Bortezomib, Melphalan, Dexamethasone and Intermittent Thalidomide (VMDT) Is an Effective Treatment for Relapsed/Refractory Myeloma: Results of a Phase II Clinical Trial.
Authors: Evangelos Terpos, Athanasios Anagnostopoulos, Efstathios Kastritis, Athanasios Zomas, Christos Poziopoulos, Nikolaos Anagnostopoulos, Konstantinos Tsionos, Meletios A. Dimopoulos
Journal: Blood (2005)
CRYOBALLOON VERSUS RADIOFREQUENCY ABLATION OF ATRIAL FIBRILLATION: IN-LAB COMPLICATION RATES AT A LARGE VOLUME ELECTROPHYSIOLOGY CENTER
Authors: Jeffrey Turner, Dilesh Patel, Anish Amin, Jose Torres, German Kamalov, Sunil Kumar, Steven Kalbfleisch, Raul Weiss, Emile Daoud, Ralph Augostini, Jaret Tyler, Zhenguo Liu, Abigail Shoben, Mahmoud Houmsse, John Hummel
Journal: Journal of the American College of Cardiology (2017)
A Phase I Safety Study of Enzastaurin Plus Bortezomib in the Treatment of Relapsed or Refractory Multiple Myeloma.
Authors: Irene M Ghobrial, Nikhil C Munshi, Brianna N Harris, Zheng Yuan, Nichole M Porter, Robert L Schlossman, Jacob P Laubach, Kenneth C. Anderson, Courtney E Lin, James E Wooldridge, Paul G Richardson, Rafat Abonour
Journal: Blood (2009)
Plasma concentrations of YKL-40 in chemo-naive patients with metastatic colorectal cancer treated with FLOX with or without cetuximab: Results from the NORDIC VII study.
Authors: Line Schmidt Tarpgaard, Tormod Kyrre Guren, Bengt Glimelius, Per Pfeiffer, Elin Kure, Mette K. N. Yilmaz, Halfdan Sorbye, Nina Keldsen, Eva Skovlund, Julia S. Johansen, Kjell Magne Tveit
Journal: Journal of Clinical Oncology (2012)

3548 Background: KRAS status is presently the best biomarker to select patients with metastatic colorectal cancer (mCRC) for therapy with EGFR inhibition even though not confirmed in all phase III studies. In the NORDIC VII study a survival benefit of adding cetuximab to the Nordic FLOX regimen could not be confirmed. Identification of new predictive and prognostic biomarkers is essential. Plasma concentration of YKL-40 is emerging as a new biomarker in patients with cancer and inflammatory diseases. We tested the hypothesis that high plasma YKL-40 associates with short progression free survival (PFS) and short overall survival (OS) in patients included in the NORDIC VII Study. Methods: 566 patients with mCRC were randomized to: A) Nordic FLOX; B) FLOX + cetuximab; and C) FLOX for 16 weeks + cetuximab continuously. Plasma samples were available from 510 patients (90%). Pretreatment plasma YKL-40 was determined by ELISA (Quidel), and the plasma YKL-40 concentration was dichotomized according to the age-corrected 95% YKL-40 level in 3130 healthy subjects. Results: Plasma YKL-40 was elevated in 204 patients (40%) and the median plasma YKL-40 was higher in the study group compared to healthy subjects (120 mg/l vs. 40 mg/l, p&lt;0.001). Elevated plasma YKL-40 was associated with short PFS (HR=1.25, 95% CI 1.04-1.51, p=0.02). This relationship was demonstrated only in patients treated with FLOX chemotherapy alone (HR=1.42, 1.02-1.98, p=0.04). High plasma YKL-40 was associated with short OS in all patients (HR=1.55, 1.25-1.92, p&lt;0.001) and in the different treatment groups (A: HR=1.54, 1.05-2.26, p=0.03; B: HR=1.40, 0.97-2.01, p=0.07; C: 1.79, 1.23-2.60, p=0.002). Multivariate analysis (YKL-40, performance status, number of metastatic sites) demonstrated that elevated plasma YKL-40 was an independent biomarker of short OS (HR=1.46, 1.17-1.81, p=0.001). Conclusions: Plasma YKL-40 may be a new prognostic biomarker in patients with mCRC treated with 1st line FLOX chemotherapy, with or without cetuximab. The predictive value of plasma YKL-40 is not yet clarified.
Glucocorticoid receptor promotes the function of myeloid-derived suppressor cells by suppressing HIF1α-dependent glycolysis
Authors: Yun Lu, Huanrong Liu, Yujing Bi, Hui Yang, Yan Li, Jian Wang, Zhengguo Zhang, Yu Wang, Chunxiao Li, Anna Jia, Linian Han, Ying Hu, Yong Zhao, Ruoning Wang, Guangwei Liu
Journal: Cellular and Molecular Immunology (2017)

Immunomodulatory signaling imposes tight regulations on metabolic programs within immune cells and consequentially determines immune response outcomes. Although the glucocorticoid receptor (GR) has been recently implicated in regulating the function of myeloid-derived suppressor cells (MDSCs), whether the dysregulation of GR in MDSCs is involved in immune-mediated hepatic diseases and how GR regulates the function of MDSCs in such a context remains unknown. Here, we revealed the dysregulation of GR expression in MDSCs during innate immunological hepatic injury (IMH) and found that GR regulates the function of MDSCs through modulating HIF1α-dependent glycolysis. Pharmacological modulation of GR by its agonist (dexamethasone, Dex) protects IMH mice against inflammatory injury. Mechanistically, GR signaling suppresses HIF1α and HIF1α-dependent glycolysis in MDSCs and thus promotes the immune suppressive activity of MDSCs. Our studies reveal a role of GR-HIF1α in regulating the metabolism and function of MDSCs and further implicate MDSC GR signaling as a potential therapeutic target in hepatic diseases that are driven by innate immune cell-mediated systemic inflammation.
DOXORUBICIN-ASSOCIATED CARDIAC TISSUE REMODELING IN BREAST CANCER PATIENTS: A CARDIAC MAGNETIC RESONANCE STUDY
Authors: Thiago Quinaglia Silva, Ferreira de Souza Thiago, Felipe Osorio Costa, Tom Neilan, Ravi Shah, Velloso Licio, Wilson Nadruz Junior, Fabricio Brenelli, Sposito Andrei Carvalho, Otavio Coelho, Michael Jerosch-Herold, Otavio Rizzi, Coelho Filho
Journal: Journal of the American College of Cardiology (2017)
Heat Shock Protein 70 Cytosolic Sequestration by Excess of Free Alpha-Globin Chains Is a Key Mechanism of the Ineffective Erythropoiesis in β-Thalassemia Major Patients
Authors: Jean-Benoît Arlet, Jean-Antoine Ribeil, Adonis Hazoumé, Samuel Demarest, Luba Tchertanov, Dussiot Michael, Ivan Cruz Moura, Thiago Maciel, Christian Auclair, Olivier Negre, Philippe Leboulch, Véronique Baudin-creuza, Carmen Garrido, Genevieve Courtois, Olivier Hermine
Journal: Blood (2012)
Erratum: Decreased IRF8 expression found in aging hematopoietic progenitor/stem cells
Authors: D L Stirewalt, Y E Choi, N E Sharpless, E L Pogosova-Agadjanyan, M R Cronk, M Yukawa, E B Larson, B L Wood, F R Appelbaum, J P Radich, S Heimfeld
Journal: Leukemia (2009)
CIRCULATING PROGENITOR CELLS LEVELS AND OUTCOMES IN ACUTE MYOCARDIAL INFARCTION
Authors: Ayman Samman Tahhan, Zakaria Almuwaqqat, Pratik Sandesara, Ayman Alkhoder, Eric Stahl, Robert Heinl, Salim Hayek, Heval Mohamed Kelli, Muhammad Hammadah, Matthew Topel, Mohamad Mazen Gafeer, Kaavya Chivukula, Hiroshi Aida, Marc Allard-Ratick, Bryan Kindya, Naser Abdelhadi, Humza Naqvi, Iraj Hesaroieh, Ernestine Mahar, Edmund Waller
Journal: Journal of the American College of Cardiology (2017)
Treatment of Patients with Steroid Refractory Acute Graft Vs Host Disease (SR-GvHD): A Matched Paired Analysis of Anti-CD26 (Begelomab) Compared to Other Treatment
Authors: Andrea Bacigalupo, H. Joachim Deeg, Dolores Caballero, Francesca Gualandi, Anna Maria Raiola, Riccardo Varaldo, Carmen Di Grazia, Lucia López Corral, Maria Teresa van Lint
Journal: Blood (2016)
Postrandomization analysis assessing survival following radiation therapy (RT) with or without 6 months of androgen suppression therapy (AST) for localized prostate cancer (PCa)
Authors: P. L. Nguyen, M. H. Chen, C. J. Beard, M. Loffredo, A. A. Renshaw, W. W. Suh, P. W. Kantoff, A. V. D'Amico
Journal: Journal of Clinical Oncology (2009)

5129 Background: 6 months of AST+RT was shown to improve survival vs. RT alone in men with unfavorable-risk localized PCa, but it is unknown if this benefit applied to all risk subgroups. Methods: Among 206 men with clinical T1b-T2b PCa and at least 1 unfavorable feature (PSA&gt;10 or Gleason &gt;=7 or MRI evidence of T3 disease) randomized to 70Gy of RT with or without 6 months of AST, we performed post-randomization subgroup analyses within four subgroups defined by both risk group (high risk [Gleason 8–10 or PSA &gt;20] or intermediate risk [all others]), and by ACE-27 comorbidity level (no/limited comorbidity or moderate/severe comorbidity). Within the 4 subgroups a log-rank test was used to compare Kaplan Meier estimates of survival (requiring p &lt; 0.05/4 or p &lt; 0.0125 to adjust for multiple comparisons) and within the 2 risk groups we used Cox multivariable analysis (MVA) to assess the association of treatment with the risk of death after adjusting for known prognostic factors. Results: After a median follow-up 8.2 yrs, 74 men died. In men with no or minimal comorbidity, estimates of survival were significantly higher among those who received AST+RT vs. RT alone, regardless of whether they had intermediate risk disease (90.9 vs. 85.8% at 7yrs, p = 0.009) or high-risk disease (88.9% vs. 51.2% at 7yrs, p = 0.007). In men with moderate or severe comorbidity, no difference in survival was observed after AST+RT vs. RT in intermediate risk (p = 0.2) or high risk (p = 0.5). After adjusting for known prognostic factors, treatment with RT as compared to AST+RT was associated with an increased risk of death in men with intermediate (AHR: 3.0 [95% CI: 1.3 to 7.2]; p = 0.01) and high risk disease (AHR: 3.3 [95% CI: 0.94 to 11.3]; p = 0.06) in a model that adjusted for the interaction between treatment and comorbidity. Conclusions: Among men with T1b-T2b prostate cancer who have no or minimal comorbidity, the addition of 6 months of AST to RT was associated with improved survival in men with both intermediate risk and high-risk disease. Among men with moderate to severe comorbidity, neither risk group appeared to benefit from the addition of AST. No significant financial relationships to disclose.